Asset Details
Do you wish to reserve the book?
Efficacy and safety of single-dose artesunate plus sulfalene/pyrimethamine combined with praziquantel for the treatment of children with Schistosoma mansoni or Schistosoma haematobium in western Kenya: a randomised, open-label controlled trial
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Efficacy and safety of single-dose artesunate plus sulfalene/pyrimethamine combined with praziquantel for the treatment of children with Schistosoma mansoni or Schistosoma haematobium in western Kenya: a randomised, open-label controlled trial
Do you wish to request the book?
Efficacy and safety of single-dose artesunate plus sulfalene/pyrimethamine combined with praziquantel for the treatment of children with Schistosoma mansoni or Schistosoma haematobium in western Kenya: a randomised, open-label controlled trial
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Efficacy and safety of single-dose artesunate plus sulfalene/pyrimethamine combined with praziquantel for the treatment of children with Schistosoma mansoni or Schistosoma haematobium in western Kenya: a randomised, open-label controlled trial
2024
Overview
Background
Reliance on praziquantel for the treatment and control of schistosomiasis is likely to facilitate the emergence of drug resistance. Combination therapy targeting adult and juvenile schistosome worms is urgently needed to improve praziquantel efficacy and delay the potential development of drug resistance. We assessed the efficacy and safety of single-dose praziquantel combined with single-dose artesunate plus sulfalene-pyrimethamine in the treatment of Kenyan children with schistosomiasis.
Methods
This was an open-label, randomised clinical trial involving 426 school-aged children (7–15 years old) diagnosed with
Schistosoma mansoni
(by Kato-Katz) or
S. haematobium
(by urine filtration). They were randomly assigned (1:1:1) to receive a single dose of praziquantel (40 mg/kg), a single dose of artesunate plus sulfalene-pyrimethamine (12 mg/kg artesunate) or combination therapy using a single dose of praziquantel (40 mg/kg) combined with a single dose of artesunate plus sulfalene-pyrimethamine (12 mg/kg artesunate). The primary outcome was cure and egg reduction rates at 6 weeks post-treatment in the available case population. Adverse events were assessed within 3 h after treatment.
Results
Of the 426 children enrolled, 135 received praziquantel, 150 received artesunate plus sulfalene-pyrimethamine, and 141 received combination therapy. Outcome data were available for 348 (81.7%) children. For
S. mansoni
-infected children (
n
= 335), the cure rates were 75.6%, 60.7%, and 77.8%, and the egg reduction rates were 80.1%, 85.0%, and 88.4% for praziquantel, artesunate plus sulfalene-pyrimethamine, and combination therapy, respectively. For
S. haematobium
-infected children (
n
= 145), the corresponding cure rates were 81.4%, 71.1%, and 82.2%, and the egg reduction rates were 95.6%, 97.1%, and 97.7%, respectively. Seventy-one (16.7%) children reported mild-intensity adverse events. The drugs were well tolerated and no serious adverse events were reported.
Conclusions
A single oral dose of praziquantel combined with artesunate plus sulfalene-pyrimethamine cured a high proportion of children with
S. haematobium
but did not significantly improve the treatment efficacy for either urinary or intestinal schistosomiasis. Sequential administration of praziquantel and artesunate plus sulfalene-pyrimethamine may enhance the efficacy and safety outcomes.
Graphical abstract
Publisher
BioMed Central,BioMed Central Ltd,BMC
Subject
/ adults
/ Animals
/ Anthelmintics - administration & dosage
/ Anthelmintics - adverse effects
/ Anthelmintics - therapeutic use
/ Artemisinin-based combinations
/ Artemisinins - administration & dosage
/ Artemisinins - adverse effects
/ Artemisinins - therapeutic use
/ Artesunate - administration & dosage
/ Artesunate - therapeutic use
/ Artesunate plus sulfalene-pyrimethamine
/ Biomedical and Life Sciences
/ Child
/ eggs
/ Female
/ Humans
/ Kenya
/ Male
/ Praziquantel - administration & dosage
/ Praziquantel - adverse effects
/ Praziquantel - therapeutic use
/ Pyrimethamine - administration & dosage
/ Pyrimethamine - adverse effects
/ Pyrimethamine - therapeutic use
/ Schistosoma haematobium - drug effects
/ Schistosoma mansoni - drug effects
/ Schistosomiasis haematobia - drug therapy
/ Schistosomiasis mansoni - drug therapy
/ Sulfalene - administration & dosage
/ urine
/ Veterinary Medicine/Veterinary Science
/ Virology
